

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (currently amended): ~~An agent~~ A composition for preventing or treating chronic pelvic pain syndrome, which comprises a phosphodiesterase 4 (PDE 4) inhibitor, or a pharmaceutically acceptable salt thereof, as an active ingredient.
2. (currently amended): The composition ~~agent~~ described in claim 1, wherein the PDE 4 inhibitor is a compound selected from the group consisting of roflumilast, cilomilast, 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid, 4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine, and pharmaceutically acceptable salts thereof.
3. (currently amended): The ~~agent~~composition described in any one of claims 1 and 2, wherein the chronic pelvic pain syndrome is interstitial cystitis.
4. (canceled).
5. (canceled).
6. (canceled).

7. (canceled).
8. (new): The composition described in claim 1, which further comprises a carrier.
9. (new): A method of preventing or treating chronic pelvic pain syndrome comprising administering an effective amount of a PDE 4 inhibitor, or pharmaceutically acceptable salt thereof, to a subject.
10. (new): The method of claim 9, wherein the PDE 4 inhibitor is a compound selected from the group consisting of roflumilast, cilomilast, 3-[4-(3-chlorophenyl)-1-ethyl-7-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-3-yl]propanoic acid, 4-(4-{4-[6-(3,4-dimethoxyphenyl)pyridine-2-carbonyl]piperazin-1-yl}phenyl)morpholine, and pharmaceutically acceptable salts thereof.
11. (new): The method described in any one of claims 9 and 10, wherein the chronic pelvic pain syndrome is interstitial cystitis.